AbbVie Showcases Advancement of Solid Tumor Pipeline at ESMO 2024, with New Data in ...

September 9, 2024

AbbVie presents new data on its ADC platform at ESMO 2024, including results from the PICCOLO trial on mirvetuximab soravtansine for platinum-sensitive ovarian cancer, PROs from the LUMINOSITY trial on telisotuzumab vedotin in advanced NSCLC, and safety/efficacy data from a Phase 1 study of ABBV-400 in pre-treated NSCLC and GEA patients.

Related Clinical Trials

Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian Cancer

Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer

A Study of NVL-655 in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)

Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 as Monotherapy and in Combination With IV Bevacizumab

A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Ovarian, Fallopian Tube, or Peritoneal Cancer (GLORIOSA)

Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil, Folinic Acid, and Bevacizumab

Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400

Reference News

news.abbvie.com

AbbVie Showcases Advancement of Solid Tumor Pipeline at ESMO 2024, with New Data in ...

investing.com

Nuvalent reports progress in cancer drug trials at ESMO 2024 - Investing.com

Nuvalent presented updated Phase 1 data from ALKOVE-1 and ARROS-1 trials at ESMO 2024, showing durability of NVL-655 and zidesamtinib in treating heavily pre-treated cancer patients. The data supports ongoing Phase 2 studies, which could potentially support future marketing applications. Nuvalent also shared new preclinical data on zidesamtinib's intracranial activity, avoiding TRK inhibition-related neurological toxicities. The company plans to discuss these updates in a conference call on September 14, 2024, and aims to develop NVL-655 and zidesamtinib as front-line treatments for ALK- or ROS1-positive NSCLC.

prnewswire.com

Nuvalent Announces Publication in Cancer Discovery Detailing Design and ... - PR Newswire

Nuvalent's NVL-655, a selective and brain-penetrant ALK inhibitor, is detailed in a Cancer Discovery manuscript, addressing limitations of current ALK TKIs in treating ALK-positive NSCLC. Preclinical and preliminary clinical data support NVL-655's potential to overcome resistance and improve tolerability, with ongoing ALKOVE-1 trial enrollment and planned ESMO Congress presentation.

prnewswire.com

AbbVie Showcases Advancement of Solid Tumor Pipeline at ESMO 2024, with New Data in ...

AbbVie to present new data on ADCs at ESMO 2024, including results from Phase 2 PICCOLO trial on mirvetuximab soravtansine for platinum-sensitive ovarian cancer and Phase 2 LUMINOSITY trial on telisotuzumab vedotin for advanced NSCLC. Also, new safety and efficacy data from Phase 1 study of ABBV-400 in pre-treated NSCLC and GEA patients.